Effect of Preadministration of Nalmefene on Sufentanil-Induced Cough During Induction of General Anesthesia in Patients Undergoing Breast Surgery: A Double-Blind Randomized Controlled Trial
DOI: https://doi.org/10.2147/dddt.s462710
IF: 4.3188
2024-05-29
Drug Design Development and Therapy
Abstract:Weiji Xie, 1, &ast Honglian He, 2, &ast Jishuang Hong, 3 Chengfei Feng, 1 Wei Li, 1 Yongchun Li 1 1 Department of Anesthesiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China; 2 Department of Anesthesiology, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, People's Republic of China; 3 Department of Anesthesiology, Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, 510060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yongchun Li; Wei Li, Department of Anesthesiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China, Email ; Purpose: This study was designed to investigate the effects of preadministration of nalmefene before general anesthesia induction on sufentanil-induced cough (SIC) in patients undergoing breast surgery. Patients and Methods: A total of 105 patients scheduled for elective breast surgery under general anesthesia were selected and randomly assigned into three groups: normal saline (Group C), low-dose nalmefene 0.1 μg·kg − 1 (Group LN), and high-dose nalmefene 0.25 μg·kg − 1 (Group HN). Sufentanil 0.5 μg·kg − 1 was injected intravenously within 2 s after 5 min of intervention. The count and severity of cough within 2 min after sufentanil injection, as well as the time to first cough, were recorded. In addition, we also collected intraoperative hemodynamic data, postoperative pain scores, the incidence of receiving rescue analgesics, and side effects up to 24 h after surgery. Results: Compared to Group C, the incidence of SIC was significantly lower in Group LN and HN (64.7% vs 30.3% and 14.7%, respectively; P < 0.001), but no significant difference was observed between the two groups ( P =0.126). Compared to Group C, the risk factors decreased by 53.4% (95% confidence interval [CI] =0.181– 0.735, P =0.008) in Group LN and by 75.9% (95% CI=0.432– 0.898, P =0.001) in Group HN. Of the patients with SIC, less frequent SIC within 2 min after induction and a lower proportion of severe coughs were observed than Group C ( P < 0.05), and no difference was detected between Group LN and HN. Additionally, the onset time to the first SIC did not differ significantly between the groups. Intraoperative hemodynamic data, postoperative pain scores, and side effects in the first 24 h did not differ among the groups. Conclusion: Preadministration of nalmefene prior to induction of general anesthesia effectively suppressed SIC in patients undergoing breast surgery, without affecting intraoperative hemodynamic fluctuation and postoperative pain intensity. Keywords: nalmefene, general anesthesia, sufentanil, cough, breast surgery Sufentanil, a potent mu-opioid receptor agonist with rapid action, strong analgesic, prolonged duration, stable hemodynamics, and a high treatment index, is an ideal opioid analgesic in the induction of general anesthesia. 1,2 However, sufentanil-induced cough (SIC) is common in anesthesia practice. 3,4 Sometimes, the cough is mild and self-limiting, but when it is severe, SIC can increase the risk of aspiration pneumonia, 5 postoperative nausea and vomiting, 6 and even undesirable pressure increase in the coelomic cavity, which can lead to severe adverse outcomes in critically ill patients. A severe cough reflex may also cause multiple subconjunctival hemorrhages and periorbital ecchymosis, 7 and further increase the risk of aspiration pneumonia. 8 Therefore, SIC prevention is urgently required. Although the precise mechanism underlying SIC remains unclear, it is widely believed that the agonistic effect of mu2-opioid receptors located on the surface of the tracheobronchial tree plays a significant role. 9,10 In clinical settings, nalmefene, a mu-/delta-opioid receptor antagonist and kappa-opioid receptor partial agonist, 11 is used to reverse opioid side effects. 12,13 The side effects associated with nalmefene are mild, including nausea or vomiting. Animal experiments have shown the cough-depressant effects of opioid antagonists on the capsaicin-induced cough reflex in mice and rats. 14–16 However, it has not yet been determined whether the ant -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal